AstraZeneca PLC

As of June 30, 2026, AstraZeneca PLC carries a market capitalization of 255.27B, placing it among publicly traded companies globally. Its enterprise value stands at 279.21B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

AstraZeneca PLC's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, AstraZeneca PLC has 1.55B shares outstanding.

As of June 30, 2026, AstraZeneca PLC trades at a trailing price-to-earnings ratio of 27.91. The price-to-sales ratio is 4.75, and the price-to-book ratio stands at 5.80.

As of June 30, 2026, AstraZeneca PLC trades at an EV/EBITDA multiple of 15.88 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.20 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 22.83 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. AstraZeneca PLC trades at an EV/FCF ratio of 42.56, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 279.21B versus a market cap of 255.27B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, AstraZeneca PLC maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 64.00, indicating elevated leverage, while an interest coverage ratio of 11.50 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, AstraZeneca PLC posted a return on equity (ROE) of 21.99, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 14.22 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.15, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 14.84, useful for judging operating efficiency across full business cycles. The company generates approximately 561,564.66 in revenue per employee across its workforce of 95,650.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.66 indicates how many times AstraZeneca PLC sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, AstraZeneca PLC recorded 1.87B in income tax expense. That works out to an effective tax rate of 16.95, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 11.02B, leaving 9.14B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on August 5, 2026, AstraZeneca PLC's stock has gained approximately 9.80% over the past 52 weeks. The 50-day moving average sits at 153.89, while the 200-day moving average is 158.34.

Over the twelve months ended June 30, 2026, AstraZeneca PLC generated 53.71B in revenue and converted that into 9.14B in net income, yielding earnings per share of 5.86. EBITDA reached 17.58B, while operating income came in at 12.23B.

As of June 30, 2026, AstraZeneca PLC holds 4.35B in cash and equivalents against 28.22B in total debt, resulting in a net debt position of 21.53B. Total book value stands at 44.02B, with working capital of -3.14B providing operational flexibility.

AstraZeneca PLC produced 11.99B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -6.70B in capital expenditures, free cash flow totaled 5.29B - equivalent to 3.41 per share.

Over the twelve months ended June 30, 2026, AstraZeneca PLC posted a gross margin of 81.88, reflecting its pricing power and cost economics. The operating margin of 22.77 and net profit margin of 17.02 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, AstraZeneca PLC paid dividends of 2.77 per share. The dividend payout ratio of 46.86 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 2.06, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.63, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to AstraZeneca PLC shareholders.

As of June 30, 2026, AstraZeneca PLC has an Altman Z-Score of 4.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.